Detailed Narrative
Strong Q4 and FY25 Performance Driven by Core and Emerging Centers
Health.Global reported a robust Q4 FY25, with revenue (excluding Milann) growing 20% YoY to INR571.1 crores, and full-year revenue reaching INR2,165.1 crores, up 17%. Adjusted EBITDA for Q4 stood at INR106.9 crores, a 14% YoY increase, with a margin of 18.3%. For the full year, adjusted EBITDA was INR396.3 crores, up 17%, with a margin of 17.8%. Emerging centers demonstrated exceptional performance in Q4 FY25, with revenue growing 32% and EBITDA increasing 44%, while established centers also showed strong growth with a 22% revenue increase and 15% EBITDA growth.
Strategic Expansion and Infrastructure Upgrades Underway
HCG continued its strategic expansion and infrastructure upgrades, including the acquisition of MG Hospital in Vizag and the addition of 5 state-of-the-art linear accelerator machines. The company inaugurated its flagship 189-bedded HCG Cancer Center in Ahmedabad, projected to increase patient footfall by 30-40%. Additionally, two new hospitals are planned for Bangalore in H2 FY26, contributing to the target of operationalizing over 900 beds within the next three years. The company plans a capex of INR286 crores for FY26 for network expansion and technology upgrades.
Profitability Impacted by Investments, Future Outlook Positive
The company's significant investments in expansion and acquisitions led to ROU creation of INR275 crores and fixed assets addition of INR400 crores, resulting in a net debt increase of INR250 crores. This, along with increased depreciation and interest costs (totaling INR25 crores), impacted PAT, which stood at INR7 crores for Q4 and INR44 crores for FY25. However, management anticipates PAT normalization as EBITDA scales from these new investments, with an overall EBITDA margin target in the 'low 20s' as emerging centers mature.
Digital Transformation and Enhanced Patient Engagement
HCG's digital revenue doubled over the past year, driven by initiatives like the launch of its official mobile app for appointments, virtual consultations, and report access. The company is committed to further scaling its digital presence, expecting it to become a significant contributor to top-line growth by enhancing patient experience and reach. This digital focus complements the company's integrated approach to cancer care, aiming to make services more accessible and data-driven.
Milann Divestment and Capital Structure Optimization
The Milann business continued to struggle, and management confirmed its intention to divest it, with a proposal expected to be finalized within the current fiscal year (FY26). Furthermore, with new investors (KKR) coming in as CVC dilutes its stake, the company is exploring the possibility of a primary equity infusion to reduce debt. This move is expected to improve interest costs and PAT, aligning with the company's long-term vision for growth and a stronger capital structure.
ARPOB Trends and Competitive Positioning
The network-wide ARPOB increased by 4% to INR44,236, with emerging centers showing a 12.4% growth to INR66,755. ARPOB in metro cities like Bangalore and Ahmedabad is significantly higher, reaching up to INR1 lakh, while Tier 2 cities are around INR30,000-35,000. For FY26, the company expects ARPOB to increase by 7-8% due to decreasing length of stay and high-end treatment modalities. Management emphasized HCG's single-specialty focus, quality outcomes, and advanced technology as key differentiators against multi-specialty competitors, leading to market share gains in key regions.